Seeing the Forest Through the Trees: Improving Adherence Alone Will Not Optimize Medication Use.

Abstract:

UNLABELLED:Medication adherence is a problem that has received widespread attention in the medical literature and health policy circles. With the increased emphasis on recognizing and rewarding quality in the U.S. health care system, medication adherence measures are increasingly being adopted to assess quality of medication use. However, when adherence is discussed in the literature or evaluated via quality measures, there is rarely any dialogue surrounding adherence in the context of patient-centered issues such as clinical status, individualized medication needs, or personal expectations and social situation. When nonadherence is identified via a comprehensive assessment of all of a patient's medication-related issues, it typically is recognized as only the third most frequent type of medication-related problem. Issues such as requiring a medication that has not been prescribed or receiving a medication prescribed at a dose too low to achieve the intended clinical goal are more frequently experienced. Furthermore, if a patient is nonadherent to a medication because of adverse effects or if the medication prescribed is not appropriate considering the patient's individual clinical situation, promoting adherence can create unintended harm. Therefore, achieving medication adherence as typically evaluated via existing quality metrics such as proportion of days covered is only valid if the medication is first deemed to be indicated, effective, and safe for the patient. Medications are the most common medical intervention for chronic illnesses. As a result, success in achieving the Triple Aim of health care is highly dependent on optimizing medication use. When quality measures for medication use narrowly focus on measuring adherence, the resulting programs of payers and providers will likely ignore the most frequent types of medication problems that prevent improved health, create unnecessary costs, and could negatively impact patients' experience with the health care system. Strong leadership and advocacy on the part of agencies in the position to influence the quality measurement landscape in the U.S. health care system will be critical to achieve widespread awareness of medication nonadherence in the context of the full scope of medication-related problems in health care. DISCLOSURES:No outside funding supported this research. Brummel provides consulting services to other health systems; has received grants from Sanofi and speaking fees from AMCP, APhA, and ASHP; and is on the faculty at the University of Minnesota and employed by Fairview Pharmacy Services. Ekstrand provides consulting services for Alliance for Integrated Medication Management and has received speaking fees from International Diabetes Center and MN Alliance of Physician Assistants. The authors report no other conflict of interest, potential or otherwise. Study concept and design were contributed primarily by Sorensen, Brummel, and Rehrauer, along with the other authors. Rehrauer, Brummel, and Ekstrand collected the data, which were interpreted by Sorensen, Brummel, Rehrauer, and Ekstrand. Pestka and Sorensen wrote and revised the manuscript, with assistance from the other authors.

authors

Sorensen TD,Pestka DL,Brummel AR,Rehrauer DJ,Ekstrand MJ

doi

10.18553/jmcp.2016.22.5.598

subject

Has Abstract

pub_date

2016-05-01 00:00:00

pages

598-604

issue

5

eissn

2376-0540

issn

2376-1032

journal_volume

22

pub_type

杂志文章
  • A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines.

    abstract:BACKGROUND:Allergic rhinitis (AR) is a common condition that can be treated with a number of different therapies. Treatments such as intranasal antihistamines (INAs) and intranasal steroids (INSs) are widely used by AR patients. For some allergy sufferers, a combination of therapies, specifically an INA and an INS, is ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.12.1426

    authors: Harrow B,Sedaghat AR,Caldwell-Tarr A,Dufour R

    更新日期:2016-12-01 00:00:00

  • Evaluation of Bedside Delivery of Medications Before Discharge: Effect on 30-Day Readmission.

    abstract:BACKGROUND:This study is an evaluation of a discharge intervention that occurred in multiple hospitals across Maryland. In this program, patients received medications at their bedside before discharge with the goal of reducing the risk of primary nonadherence to prescribed medications. OBJECTIVE:To test if the interve...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,多中心研究

    doi:10.18553/jmcp.2020.26.3.296

    authors: Segal JB,Apfel A,Brotman DJ,Shermock KM,Clark JM

    更新日期:2020-03-01 00:00:00

  • Current Procedural Terminology Codes for Medication Therapy Management in Administrative Data.

    abstract:BACKGROUND:Three pharmacist-specific Current Procedural Terminology (CPT) codes exist to facilitate medication therapy management (MTM) reimbursement (codes 99605, 99606, and 99607). However, no studies have used CPT codes in administrative claims databases to identify subjects who have received MTM services. OBJECTIV...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.10.1297

    authors: Axon DR,Chinthammit C,Tate J,Taylor AM,Leal S,Pickering M,Black H,Warholak T,Campbell PJ

    更新日期:2020-10-01 00:00:00

  • A Sleeping Giant: Community Pharmacy's Potential Is Unrivaled.

    abstract:DISCLOSURES:No funding was received for the writing of this commentary. The author has nothing to disclose. ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.6.705

    authors: Trygstad T

    更新日期:2020-06-01 00:00:00

  • Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.

    abstract:BACKGROUND:Acromegaly is a chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels most often caused by a pituitary adenoma. Clinical presentation of the disease includes coarsening of the facial features, soft-tissue swelling of the hands and feet, and overgro...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.12.1106

    authors: Placzek H,Xu Y,Mu Y,Begelman SM,Fisher M

    更新日期:2015-12-01 00:00:00

  • A Physician's Perspective on Generic Drug Quality.

    abstract:DISCLOSURES:No funding supported the writing of this article. The author has nothing to disclose. ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.5.592

    authors: Lever HM

    更新日期:2020-05-01 00:00:00

  • Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model.

    abstract:BACKGROUND:Adherence to treatment is correlated with treatment success in chronic myeloid leukemia (CML). CVS Specialty explored novel methods to improve adherence in this population to ensure optimal adherence and lower the risk of unsuccessful treatment. One novel program explored involved an interactive 2-way clinic...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.11.1290

    authors: Sawicki C,Friend KE,Patel R,Polinski JM,Singh S

    更新日期:2019-11-01 00:00:00

  • Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.

    abstract:BACKGROUND:Costs associated with biologic switching and discontinuation can be high in chronic inflammatory diseases. Inappropriate use of medications may have cost implications for both payers and patients. Understanding of biologic utilization and switching rates is lacking among patients with ankylosing spondylitis ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.19433

    authors: Yi E,Dai D,Piao OW,Zheng JZ,Park Y

    更新日期:2021-01-01 00:00:00

  • Letter--The Authors Respond.

    abstract:DISCLOSURES:No additional funding was received for the writing of this letter. The published study referred to in this letter was funded by Janssen Scientific Affairs, which employs Maiese and funded Cornerstone Research Group, a health economic consulting group, to conduct the study. Grima is a founding partner of Cor...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.9.1028

    authors: Hollmann S,Moldaver D,Goyert N,Grima D,Maiese EM

    更新日期:2019-09-01 00:00:00

  • Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.

    abstract:BACKGROUND:Formulary management within a limited budget is critical, especially for specialty drugs, which are used for serious medical conditions and are very expensive. Despite attempts to summarize the pertinent evidence, it is uncertain whether data needs of formulary decision makers for specialty drugs are satisfi...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.4.368

    authors: Choi Y,Navarro RP

    更新日期:2016-04-01 00:00:00

  • Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.

    abstract:BACKGROUND:Persistence with multiple daily insulin injections (MDI) may be challenging for patients with type 2 diabetes (T2DM). However, limited information is available regarding the effect of persistence with MDI on outcomes. OBJECTIVE:To evaluate persistence with basal and bolus insulin therapy and assess its rela...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.19097

    authors: Edelman SV,Ermakova A,Xiong Y,Sieradzan R,Taylor SD

    更新日期:2019-12-01 00:00:00

  • Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.

    abstract:BACKGROUND:Recent evidence has demonstrated that, over 12 months, pharmacy costs associated with switching nonadherent recently relapsed patients from oral atypical antipsychotics (OAAs) to once-monthly paliperidone palmitate (PP1M) were offset by reduced relapse rates and schizophrenia-related health care costs. In ad...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.2.176

    authors: El Khoury AC,Pilon D,Morrison L,Shak N,Llaneza A,Kim E,Lefebvre P

    更新日期:2020-02-01 00:00:00

  • Assessing the Population-Level Correlation of Medication Regimen Complexity and Adherence Indices Using Electronic Health Records and Insurance Claims.

    abstract:BACKGROUND:Nonadherence to medication regimens can lead to adverse health care outcomes and increasing costs. OBJECTIVES:To (a) assess the level of medication complexity at an outpatient setting using population-level electronic health record (EHR) data and (b) evaluate its association with medication adherence measur...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.7.860

    authors: Ma X,Jung C,Chang HY,Richards TM,Kharrazi H

    更新日期:2020-07-01 00:00:00

  • Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.

    abstract:BACKGROUND:Previous research finds significant variation in spending and utilization across regions, with little evidence of differences in outcomes. While such findings have been interpreted as evidence that spending can be reduced without compromising patient outcomes, the link between spending variation and outcomes...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.6.504

    authors: Baumgardner J,Shahabi A,Linthicum M,Vine S,Zacker C,Lakdawalla D

    更新日期:2018-06-01 00:00:00

  • Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes.

    abstract::BACKGROUND: Basal insulin is often recommended as the initial therapy for patients with type 2 diabetes who require insulin treatment. Adequate adherence is critical to diabetes management, yet suboptimal insulin adherence has been reported. Second-generation long-acting (SGLA) insulin has higher dosing flexibility an...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.11.1434

    authors: Zhang H,Barner JC,Moczygemba LR,Rascati KL

    更新日期:2020-11-01 00:00:00

  • Change in Proportion of Days Covered for Statins Following Implementation of a Pharmacy Student Adherence Outreach Program.

    abstract:BACKGROUND:Nearly half of statin users discontinue therapy within the first year of treatment. Nonadherence to statin therapy may lead to an increased risk of atherosclerotic cardiovascular disease and, thus, higher costs due to hospitalizations. Value-based care models, such as accountable care organizations (ACO), ar...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.5.588

    authors: Tamargo C,Sando K,Prados Y,Cowart K

    更新日期:2019-05-01 00:00:00

  • Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.

    abstract:BACKGROUND:Discarding unused drugs after dose changes or discontinuation can significantly affect pharmacy budgets. This is especially concerning for expensive oncology agents. However, few economic studies account for drug wastage, providing an inaccurate estimate of a drug's actual economic cost, cost-effectiveness, ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.8.859

    authors: Biskupiak J,Oderda G,Brixner D,Tang D,Zacker C,Dalal AA

    更新日期:2019-08-01 00:00:00

  • Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.

    abstract:BACKGROUND:The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology has revolutionized the treatment of neovascular age-related macular degeneration (nAMD). Despite this significant progress, gaps and challenges persist in the diagnosis of nAMD, initiation of treatment, and managem...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,评审

    doi:10.18553/jmcp.2018.24.2-a.s3

    authors: Wykoff CC,Clark WL,Nielsen JS,Brill JV,Greene LS,Heggen CL

    更新日期:2018-02-01 00:00:00

  • The Effect of Clinical Pharmacist-Led Comprehensive Medication Management on Chronic Disease State Goal Attainment in a Patient-Centered Medical Home.

    abstract:BACKGROUND:Clinical pharmacy services were initiated at 7 of 11 clinics within a primary care network (PCN), which was designated as a patient-centered medical home and was affiliated with a large academic medical center in October 2014. The goal of the service was to target patients with uncontrolled chronic condition...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.5.423

    authors: Prudencio J,Cutler T,Roberts S,Marin S,Wilson M

    更新日期:2018-05-01 00:00:00

  • Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.

    abstract:BACKGROUND:The functional impairment associated with migraine can cause physical, emotional, and economic ramifications that can affect occupational, academic, social, and family life. Understanding the relationship between headache-free days (HFDs) and the disease burden of migraine may help with decisions regarding t...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.20103

    authors: Lipton RB,Lee L,Saikali NP,Bell J,Cohen JM

    更新日期:2020-10-01 00:00:00

  • Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.

    abstract:BACKGROUND:The Biologics Price Competition and Innovation Act, introduced as part of the Affordable Care Act, directed the FDA to create an approval pathway for biologic products shown to be biosimilar or interchangeable with an FDA-approved innovator drug. These biosimilars will not be chemically identical to the refe...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.1.23

    authors: AMCP Task Force on Biosimilar Collective Intelligence Systems.,Baldziki M,Brown J,Chan H,Cheetham TC,Conn T,Daniel GW,Hendrickson M,Hilbrich L,Johnson A,Miller SB,Moore T,Motheral B,Priddy SA,Raebel MA,Randhawa G,Surratt

    更新日期:2015-01-01 00:00:00

  • Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice.

    abstract:BACKGROUND:Allergy immunotherapy (AIT) is the only available treatment that alters the natural course of allergies and has possible disease-modifying effects. AIT is administered primarily via subcutaneous injection delivered in a physician's office. Few studies have been conducted in the United States or Canada to eva...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,多中心研究

    doi:10.18553/jmcp.2015.21.11.982

    authors: Blume SW,Yeomans K,Allen-Ramey F,Smith N,Kim H,Lockey RF,Nichol MB

    更新日期:2015-11-01 00:00:00

  • Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.

    abstract:BACKGROUND:Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process. OBJECTIVE:To evaluate the cost-effectiveness of a pharmacogenetic test (...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.8.726

    authors: Groessl EJ,Tally SR,Hillery N,Maciel A,Garces JA

    更新日期:2018-08-01 00:00:00

  • A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.

    abstract:BACKGROUND:Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and edoxaban-are at least as effective and safe as warfarin for the risk of stroke/systemic embolism (SE) and major bleeding (MB) in patients with atrial fibrillation (AF). However, few studies hav...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.9.911

    authors: Amin A,Keshishian A,Trocio J,Dina O,Le H,Rosenblatt L,Liu X,Mardekian J,Zhang Q,Baser O,Nadkarni A,Vo L

    更新日期:2018-09-01 00:00:00

  • Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization.

    abstract:BACKGROUND:Gout, hyperuricemia, and cardiovascular disease (CVD) are prevalent conditions in the United States, and while they share common risk factors such as obesity, hypertension, hypercholesterolemia, and type 2 diabetes mellitus, relatively little is known about what patient and disease characteristics may link C...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.6.677

    authors: Pillinger MH,Bangalore S,Klein AB,Baumgartner S,Morlock R

    更新日期:2017-06-01 00:00:00

  • THE AUTHORS RESPOND.

    abstract::DISCLOSURES: Funding for the study referred to in this letter was contributed by Bayer Healthcare. Xia and Williamson are employees of Bayer Healthcare. Roth, Carlson, and Sullivan are consultants to Bayer Healthcare. Carlson also reports fees from Adaptive Biotechnologies, unrelated to the study. Roth reports consult...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 信件

    doi:10.18553/jmcp.2020.26.12.1617

    authors: Roth JA,Carlson JJ,Xia F,Williamson T,Sullivan SD

    更新日期:2020-12-01 00:00:00

  • Evaluating Patient Preferences for Different Incentive Programs to Optimize Pharmacist-Provided Patient Care Program Enrollment.

    abstract:BACKGROUND:Employers have increased efforts to engage employees in health and wellness programs. Providing employees with incentives to participate in these programs has been shown to improve overall enrollment and engagement. One program that has had challenges with enrollment and engagement is medication therapy mana...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.11.1140

    authors: Tomaszewski D,Cernohous T,Vaidyanathan R

    更新日期:2017-11-01 00:00:00

  • Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.

    abstract:BACKGROUND:The implementation of Medicare Part D provided insurance coverage for outpatient medications, but when persons reach the "gap," they have very limited or no medication insurance coverage until they reach a second threshold for catastrophic coverage. In addition, some patients have a low-income subsidy (LIS),...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.8.862

    authors: Park H,Rascati KL,Lawson KA,Barner JC,Richards KM,Malone DC

    更新日期:2014-08-01 00:00:00

  • Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.

    abstract:BACKGROUND:Since multiple myeloma (MM) incurs a substantial economic burden in care management, more and more discussion has been generated in recent years about the costs of novel antimyeloma drugs and their associated value. Because of these costs, economic assessment that quantifies value of care over the long-term ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.8.831

    authors: Chen Y,Lairson DR,Chan W,Huo J,Du XL

    更新日期:2017-08-01 00:00:00

  • Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.

    abstract:BACKGROUND:Despite multiple treatment options, the prognosis of pulmonary arterial hypertension (PAH) remains poor. PAH patients experience a high economic burden due to comorbidities, hospitalizations, and medication costs. Although combination therapy has been shown to reduce hospitalizations, the relationship betwee...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.17391

    authors: Burger CD,Ozbay AB,Lazarus HM,Riehle E,Montejano LB,Lenhart G,White RJ

    更新日期:2018-08-01 00:00:00